title: Mycobacterium chelonae bacteremia after first dose of infliximab for ulcerative colitis.
authors.affiliation: Gastrointestinal Unit, Crohn's and Colitis Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: Dmitriy
authors.initials: D
authors.lastname: Kedrin
authors.affiliation: Laboratory Medicine, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: Ricard
authors.initials: R
authors.lastname: Masia
authors.affiliation: Laboratory Medicine, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: Rosalynn M
authors.initials: RM
authors.lastname: Nazarian
authors.affiliation: Gastrointestinal Unit, Crohn's and Colitis Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: John J
authors.initials: JJ
authors.lastname: Garber
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D016470:Bacteremia / Q000139:chemically induced* / Q000382:microbiology; D060085:Coinfection / Q000382:microbiology; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D000069285:Infliximab; D007710:Klebsiella Infections / Q000150:complications; D007711:Klebsiella pneumoniae; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications* / Q000382:microbiology; D016926:Mycobacterium chelonae
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab